Abstract |
No effective treatment has been shown for patients with acute transverse myelopathy. In an open study five children with severe acute transverse myelopathy were treated with intravenous methylprednisolone and compared with a historical group of 10 patients. The results show that in the methylprednisolone treatment group compared with the historical group of 10 patients: the median time to walk independently was significantly reduced (23 v 97 days); the proportion of patients with a full recovery within 12 months was significantly higher (80 v 10%); all patients had complete motor recovery within one year in contrast with only two of 10 patients in the historical group; and serious adverse effects did not occur. This pilot study suggests that high dose methylprednisolone is effective in the treatment of acute transverse myelopathy.
|
Authors | G Sébire, H Hollenberg, L Meyer, G Huault, P Landrieu, M Tardieu |
Journal | Archives of disease in childhood
(Arch Dis Child)
Vol. 76
Issue 2
Pg. 167-8
(Feb 1997)
ISSN: 1468-2044 [Electronic] England |
PMID | 9068313
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Glucocorticoids
- Methylprednisolone
|
Topics |
- Acute Disease
- Child
- Drug Administration Schedule
- Female
- Glucocorticoids
(therapeutic use)
- Humans
- Male
- Methylprednisolone
(therapeutic use)
- Myelitis, Transverse
(drug therapy)
- Pilot Projects
- Treatment Outcome
|